Trial Profile
Safety and efficacy of fixed-dose combination of ledipasvir/sofosbuvir with or without ribavirin in patients with genotype 1 hepatitis C
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Apr 2018
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 02 Apr 2018 New trial record
- 23 Mar 2018 Results published in the Alimentary Pharmacology and Therapeutics